Barr Sued By Celgene Over Generic Thalomid

Law360, New York (January 23, 2007, 12:00 AM EST) -- Generic drug maker Barr Pharmaceuticals Inc. has triggered a patent infringement lawsuit from Celgene Corp., a New Jersey drug maker that says Barr trampled the intellectual property rights for its leading cancer treatment.

Celgene’s complaint, filed Jan. 18 in federal court for the District of New Jersey, seeks to scratch Barr's planned generic version of its costly and popular product Thalomid, which pulled in about $430 million for the company last year.

Celgene said it will put up a tough fight to keep control of Thalomid,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.